Vaxcyte, Inc. (PCVX) Stock

Vaxcyte, Inc. (PCVX) is a Healthcare stock trading at $51.44 (as of 2026-06-18), with a market capitalization of $7.42B and a trailing P/E of -7.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Vaxcyte, Inc. is a clinical-stage biotechnology company developing protein-based vaccine candidates to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-24 for invasive pneumococcal disease and pneumonia and other programs for emerging pneumococcal strains and additional bacterial targets.

Valuation — source: SEC EDGAR (first-party)
Price$51.44
Market Cap$7.42B
P/E Ratio-7.4
EV / EBITDA-6.6
Price / Book2.44
Price / Sales64.52
DCF Value (model)$-77.95
DCF Upside vs Price-251.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$119.72M
Net Margin-640.4%
Return on Equity-31.6%
Current Ratio7.49
Revenue Growth (YoY)8.8%
EPS Growth (YoY)48.2%
FCF Growth (YoY)40.9%
Financial Health — source: SEC EDGAR
Altman Z-Score12.59 (safe)
Valuation vs Sector & Industry
Stock P/E-7.4
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-135.1%
vs Industry-142.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJANUS HENDERSON GROUP PLC ($960.23M)
Institutional Holders Tracked10
Congressional Trades (recent)8
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOGrant E. Pickering
Employees414
CountryUS
IPO Date2020-06-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Krystal Biotech, Inc. (KRYS)
  • Rhythm Pharmaceuticals, Inc. (RYTM)
  • Kymera Therapeutics, Inc. (KYMR)
  • PTC Therapeutics, Inc. (PTCT)
  • Silexion Therapeutics Ltd. (SLXN)
  • Cogent Biosciences, Inc. (COGT)
  • Protagonist Therapeutics, Inc. (PTGX)
  • Apogee Therapeutics, Inc. (APGE)
PCVX earnings history · PCVX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.